FDA approves first monoclonal antibody for COPD

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00164-7

IF: 112.288

2024-10-02

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 01 October 2024; doi:10.1038/d41573-024-00164-7 FDA approves first monoclonal antibody for COPD

pharmacology & pharmacy,biotechnology & applied microbiology

What problem does this paper attempt to address?

FDA approves 100th monoclonal antibody product

Asher Mullard

DOI: https://doi.org/10.1038/d41573-021-00079-7

IF: 112.288

2021-05-05

Nature Reviews Drug Discovery

Abstract:Thirty-five years on from the FDA's approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency's new drug approvals each year. Thirty-five years on from the FDA's approval of a first monoclonal antibody, these biologics account for nearly a fifth of the agency's new drug approvals each year.

pharmacology & pharmacy,biotechnology & applied microbiology
Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

Lin TONG,Hui-fang TANG

DOI: https://doi.org/10.13683/j.wph.2017.04.014

2017-01-01

Abstract:Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent and progressive airflow limitation,which increases chronic inflammatory response in the airway with acute exacerbation and complications.Roflumilast is the only phosphodiesterase-4 inhibitor that can be oral administration for the treatment of COPD approved by the EU and FDA.Roflumilast has a strong anti-inflammatory effect and moderate bronchial dilatation,which can effectively improve lung function,and significantly reduce the deterioration in moderate and severe COPD patients,to prevent from acute exacerbations.This review summarizes the advances of roflurnilast in the clinical treatment of COPD.
FDA approves first telomerase inhibitor

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00102-7

IF: 112.288

2024-06-16

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 14 June 2024; doi:10.1038/d41573-024-00102-7 FDA approves first telomerase inhibitor

pharmacology & pharmacy,biotechnology & applied microbiology
FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor

Asher Mullard

DOI: https://doi.org/10.1038/d41573-023-00028-6

IF: 112.288

2023-02-10

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 09 February 2023; doi:10.1038/d41573-023-00028-6 FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor

pharmacology & pharmacy,biotechnology & applied microbiology
FDA approves ADC Therapeutics’ loncastuximab tesirine, ushering in a new cytotoxic payload

Asher Mullard

DOI: https://doi.org/10.1038/d41573-021-00082-y

IF: 112.288

2021-05-12

Nature Reviews Drug Discovery

Abstract:<p>Nature Reviews Drug Discovery, Published online: 12 May 2021; <a href="https://www.nature.com/articles/d41573-021-00082-y">doi:10.1038/d41573-021-00082-y</a></p>FDA approves ADC Therapeutics' loncastuximab tesirine, ushering in a new cytotoxic payload

pharmacology & pharmacy,biotechnology & applied microbiology
Network Meta-Analysis of the Efficacy and Safety of Monoclonal Antibodies and Traditional Conventional Dichotomous Agents for Chronic Obstructive Pulmonary Disease

Yu Xiong,Jia-qiang Hu,Hui-lin Tang,Zhi-xia Zhao,Li-hong Liu

DOI: https://doi.org/10.3389/fmed.2024.1334442

IF: 3.9

2024-01-01

Frontiers in Medicine

Abstract:IntroductionMonoclonal antibodies (mAbs) against cytokines and chemokines or their receptors promise to be a potential therapeutic option to address chronic obstructive pulmonary disease (COPD). We aim to provide a comprehensive literature review of the improvement in FEV1 and safety when comparing mAbs with conventional dichotomous agents.MethodsWe systematically searched 3 electronic databases (PubMed, EMBASE, and CENTRAL) up to August 1, 2023 to collect eligible randomized controlled trials (RCTs). A frequentist network meta-analysis using a random-effects model was deployed to calculate mean differences (MD) for FEV1, relative risk (RR) of treatment-emergent adverse events (TEAEs), and estimate the surface under cumulative rankings (SUCRA). A higher SUCRA indicates a better outcome.ResultsThis study included 23 RCTs involving a total of 20,853 patients. Overall, except for Dupilumab, mAbs did not significantly improve FEV1 compared to traditional conventional dichotomous agents. Among all the interventions included, Aclidinium bromide/Formoterol (AB/FF) (SUCRA 97.7%) ranked highest, followed by Umeclidinium/vilanterol (UMEC/VI) (SUCRA 93.5%), and Glycopyrrolate Formoterol Fumarate (GFF) (SUCRA 84.7%). Dupilumab (SUCRA 66.9%) ranked the fourth among all interventions but ranked the first among all the mAbs. Importantly, all mAbs demonstrated a good safety profile compared with placebo.ConclusionConsidering the improvement in FEV1 and its safety, the development of mAbs for COPD still holds significant clinical potential.Systematic review registrationPROSPERO, CRD42023452714.
FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept

Katie Kingwell

DOI: https://doi.org/10.1038/d41573-024-00054-y

IF: 112.288

2024-03-28

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 27 March 2024; doi:10.1038/d41573-024-00054-y FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept

pharmacology & pharmacy,biotechnology & applied microbiology
FDA approves first two drugs for rare Niemann–Pick disease

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00162-9

IF: 112.288

2024-09-28

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 27 September 2024; doi:10.1038/d41573-024-00162-9 FDA approves first two drugs for rare Niemann–Pick disease

pharmacology & pharmacy,biotechnology & applied microbiology
Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD

Lorraine Murphy,Stephen Rennard,James Donohue,Mathieu Molimard,Ronald Dahl,Kai-Michael Beeh,Juergen Dederichs,Hans-Jürgen Fülle,Mark Higgins,David Young

DOI: https://doi.org/10.1007/s40265-014-0284-7

2014-09-01

Drugs

Abstract:Indacaterol is the first once-daily, long-acting β2-adrenergic agonist (LABA) approved for the treatment of chronic obstructive pulmonary disease (COPD). Indacaterol was developed using a combination of informed drug design and molecular chemistry to generate a β2-adrenergic agonist with a fast onset and long duration of action, enabling once-daily dosing with an acceptable safety profile. Early preclinical studies with indacaterol demonstrated these characteristics, and this promising molecule was taken into clinical development, originally for asthma treatment. Subsequent safety concerns over LABA monotherapy in patients with asthma redirected indacaterol’s development to centre on COPD, where a good evidence base and guideline recommendations for bronchodilator monotherapy existed. Clinical development was initially complicated by different inhaler devices and differing doses of indacaterol. Using a phase III innovative adaptive-design clinical trial (INHANCE), indacaterol 150 and 300 μg once-daily doses were selected to be taken forward into the phase III INERGIZE programme. This programme delivered placebo-controlled and active-comparator data, including comparisons with formoterol, tiotropium and salmeterol/fluticasone, as well as the use of indacaterol in combination with tiotropium. Together, these studies provided a comprehensive assessment of the benefit–risk profile of indacaterol, allowing for regulatory submission. Indacaterol was first approved at once-daily doses of 150 and 300 μg in the European Union in 2009, followed by 150 µg in Japan (2011) and China (2012), and 75 μg in the United States (2011). To date, indacaterol is approved and marketed in more than 100 countries worldwide for once-daily maintenance treatment of COPD.

pharmacology & pharmacy,toxicology
FDA approves l-amino acid decarboxylase deficiency gene therapy

Asher Mullard

DOI: https://doi.org/10.1038/d41573-024-00184-3

IF: 112.288

2024-11-22

Nature Reviews Drug Discovery

Abstract:Nature Reviews Drug Discovery, Published online: 15 November 2024; doi:10.1038/d41573-024-00184-3 FDA approves l -amino acid decarboxylase deficiency gene therapy

pharmacology & pharmacy,biotechnology & applied microbiology
Next generation of anti-inflammatory therapy for COPD?

Henrik Watz

DOI: https://doi.org/10.1183/13993003.02084-2017

IF: 24.3

2017-10-01

European Respiratory Journal

Abstract:Symptomatic treatment of chronic obstructive pulmonary disease (COPD) by next-generation bronchodilators has improved considerably over the past decade: Long-acting beta-agonists and long-acting muscarinic antagonists (also as combined fixed-dose inhalation) are now available for long-term maintenance. However, there has been very little progress in developing anti-inflammatory drugs that specifically target inflammation in COPD [1]. More than 10 years ago, several inflammatory pathways and potential drugs in early-phase development for COPD were summarised in two well-known review articles [2, 3]. However, of the drug candidates listed there, only the oral phosphodiesterase-4 inhibitor roflumilast made it to regulatory approval; its anti-inflammatory effects resulted in a reduction of exacerbations and modest improvements in lung function [1, 4]. Other drugs either failed to show a clear benefit, or drug development was stopped because of safety concerns [5]. This has made the past decade disappointing for the development of novel anti-inflammatory therapies in COPD [1]. The MAPK inhibitor RV568 might be the next generation of anti-inflammatory therapy for COPD http://ow.ly/vccD30fNP3c

respiratory system
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Jordan Beveridge,Eileen Kaniecki,Aniketh Naidu,Bret David Silverglate,George Grossberg

DOI: https://doi.org/10.1080/14728214.2024.2304059

2024-01-14

Expert Opinion on Emerging Drugs

Abstract:Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.

pharmacology & pharmacy
Penpulimab: First Approval

Sohita Dhillon

DOI: https://doi.org/10.1007/s40265-021-01640-9

2021-11-23

Drugs

Abstract:Penpulimab (安尼可®) is a humanised anti-programmed cell death 1 (PD-1) monoclonal antibody developed by Akeso Biopharma, in collaboration with Chia Tai Tianqing (a subsidiary of SinoBiopharm), for the treatment of various cancers, including Hodgkin's lymphoma, nasopharyngeal cancer, non-small cell lung cancer (NSCLC) and solid tumours. Penpulimab is an immunoglobulin G1 monoclonal antibody engineered to completely eliminate Fcγ receptor binding and Fc-mediated effector functions that can compromise anti-tumour activity. In August 2021, penpulimab received its first approval in China for the treatment of adult patients with relapsed or refractory classic Hodgkin's lymphoma who have undergone at least second-line chemotherapy. Penpulimab is under regulatory review for nasopharyngeal cancer and NSCLC in China. Clinical studies of penpulimab are underway for various cancers in China and Australia. This article summarizes the milestones in the development of penpulimab leading to this first approval for relapsed or refractory classic Hodgkin's lymphoma.

pharmacology & pharmacy,toxicology
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Pallavi S Mishra-Kalyani,S. Jafri,Martha Donoghue,M. Fiero,M. Chuk,Y. Gong,Joyce Cheng,L. Pai-Scherf,Jeanne Fourie Zirkelbach,Jonathan Herz,Shyam Kalavar,Jiang Liu,Hong Zhao,Hongshan Li,Kun He,B. Osborn,Luckson N Mathieu,W. Fu,Y. Bi,Yi Ren,Rebecca Cohen,Yuan Xu,Min Wang,J. Beaver,E. Larkins,Oladimeji Akinboro,S. Sickafuse,R. Pazdur,H. Singh,I. Bulatao,Whitney S. Helms

DOI: https://doi.org/10.1158/1078-0432.CCR-21-3844

IF: 13.801

2022-01-31

Clinical Cancer Research

Abstract:FDA's approval of cemiplimab-rwlc on February 22, 2021 follows prior approvals of pembrolizumab and atezolizumab for similar indications - as first-line treatment for patients with programmed death ligand-1 (PD-L1)-high advanced non-small cell lung cancer (NSCLC). Approvals of these anti-PD-(L)-1 agents were supported by statistically significant and clinically meaningful improvements in overall survival (OS) in international, multi-center, active-controlled randomized trials. In KEYNOTE-024, the OS hazard ratio (HR) was 0.60 (95% [CI]: 0.41, 0.89; p=0.005) favoring pembrolizumab over platinum-doublet chemotherapy. In IMpower110, the OS HR was 0.59 (95% CI: 0.40, 0.89; p=0.0106) favoring atezolizumab over platinum-doublet chemotherapy. In Study 1624, the OS HR was 0.68 (95% CI: 0.53, 0.87; p=0.0022) favoring cemiplimab-rwlc over platinum-doublet chemotherapy. The PFS effect sizes for these anti-PD-(L)-1 antibodies were also comparable across their respective registrational trials, and their safety profiles were consistent with the anti-PD-(L)-1 class adverse event profile. The consistent survival benefits and manageable toxicity profiles of these single agent anti-PD-(L)-1 antibodies have established them as important treatment options in the PD-L1 high NSCLC treatment landscape. FDA approvals of these anti-PD-(L)-1 antibodies, based on their favorable benefit-risk profiles, present effective chemotherapy-free therapeutic options for patients with advanced PD-L1 high NSCLC in the United States.

Medicine
Sixty seconds on . . . asthma injections

Jacqui Wise

DOI: https://doi.org/10.1136/bmj.q2690

2024-12-03

BMJ

Abstract:What's new?Research published in the journal Lancet Respiratory Medicine found that an injection of a monoclonal antibody called benralizumab significantly reduced asthma attacks and chronic obstructive pulmonary disease (COPD) exacerbations when compared with the current standard treatment of prednisolone.1This isn't a wheeze, is it?It's no joke—and, as it's the first new treatment for asthma and COPD attacks in 50 years, people are excited. Mona Bafadhel, a professor from the King's Centre for Lung Health and lead investigator of the trial, said that the treatment could "be a game changer for people with asthma and COPD."Tell me more—I need to inhale this informationPatients with acute inflammation caused by high levels of eosinophils were included in the trial and randomly assigned to receive either a single injection of benralizumab or standard care with 30 g prednisolone daily for five days or both. After 28 days the symptoms of cough, wheeze, breathlessness, and...

medicine, general & internal
Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Alexander C Martins,Mariana Y Oshiro,Fernando Albericio,Beatriz G de la Torre

DOI: https://doi.org/10.3390/biomedicines12091992

IF: 4.757

2024-09-02

Biomedicines

Abstract:An increase in total drug (small molecules and biologics) approvals by the Food and Drug Administration (FDA) was seen in 2023 compared with the previous year. Cancer remained the disease most targeted by monoclonal antibodies (mAbs), followed by autoimmune conditions. Our data reveal the prevalence of approvals for biologics even during years when the total number of authorizations was low, such as in 2022. Over half the drugs that received the green light in 2023 benefited from expedited programs, as the incidence of many diseases increased. In addition, over half of the biologics approved received Orphan Drug Designation from the FDA. This narrative review delves into details of the most significant approvals in 2023, including mAbs, enzymes, and proteins, explaining their mechanisms of action, differences from previous drugs, placebo, and standards of care, and outcomes in clinical trials. Given the varying number of drugs authorized annually by the U.S. health authority, this review also examines the limits of external influences over the FDA's decisions and independence regarding drug approvals and withdrawals.
Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma

James A. Davis,Abigail Shockley,Ashley E. Glode

DOI: https://doi.org/10.1177/10781552211073575

2022-01-17

Journal of Oncology Pharmacy Practice

Abstract:Objective: This article summarizes the background, clinical trials, and place in therapy for the first two anti-CD19 monoclonal antibodies that have been recently FDA approved for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Summary: Treatment options are limited for patients that have relapsed after or are ineligible for autologous stem cell transplant (ASCT) or chimeric antigen receptor (CAR) T-cell therapy. Recent novel therapy approvals have started to change management strategies and outcomes for these patients. Two examples of recent FDA approvals are tafasitamab and loncastuximab tesirine, which represent the first anti-CD19 targeting monoclonal antibodies for patients with R/R DLBCL. Tafasitamab was granted accelerated approval in combination with lenalidomide for adult patients with R/R DLBCL after one or more lines of therapy based on the phase 2, L-MIND trial. Loncastuximab tesirine was granted accelerated approval for adult patients with R/R DLBCL after two or more lines of therapy based on the phase 2, LOTIS-2 trial. The place in therapy and sequencing of these agents can present a challenge to prescribers especially in regards to patients being evaluated for CD19 targeting CAR T-cell therapy. Conclusion: Tafasitamab and loncastuximab tesirine are options for use in patients with R/R DLBCL and are welcome additions to the limited therapy options for these patients. Further data is needed to elucidate sequencing and the impact these agents may have on CAR T-cell therapy. Ongoing clinical trials are studying these agents in the upfront setting in combination with other chemoimmunotherapy agents which may further expand treatment options for patients with B-cell lymphomas.

oncology,pharmacology & pharmacy
Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy

Moritz Z. Kayser,Hendrik Suhling,Jan Fuge,Christopher A. Hinze,Nora Drick,Nikolaus Kneidinger,Jürgen Behr,Christian Taube,Tobias Welte,Ina Haasler,Katrin Milger

DOI: https://doi.org/10.1186/s12890-024-02964-4

IF: 3.1

2024-03-22

BMC Pulmonary Medicine

Abstract:Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. While all biologics are efficient individually, the choice of biologic is complicated by insufficient data on their comparative long-term treatment efficacy. Here, we compare the real-life efficacy of these biologics in asthma therapy over 12 months.

respiratory system
Revefenacin: First Global Approval

Young-A Heo

DOI: https://doi.org/10.1007/s40265-018-1036-x

Drugs

Abstract:Revefenacin (YUPELRI™) inhalation solution, a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD). In November 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD. This article summarizes the milestones in the development of revefenacin leading to this first global approval.
COPD and biologic treatment: state of the art

Sebastian Ferri,Giovanni Paoletti,Corrado Pelaia,Enrico Heffler,Giorgio Walter Canonica,Francesca Puggioni

DOI: https://doi.org/10.1097/ACI.0000000000000920

2023-08-01

Abstract:Purpose of review: Chronic Obstructive Pulmonary Disease (COPD) is a common, heterogeneous disease associated with abnormal inflammatory response of the lung to noxious particles and gases. The progression of disease leads to respiratory failure, disability and premature death. Although recent progress in reducing the global burden of many chronic disease, such as heart disease and cancer, mortality and morbidity due to COPD continue to increase despite of cigarette smoking worldwide policy. Additionally, diagnostic and therapeutic options have not changed in decades. While patients affected by other respiratory disease may benefit with a personalized precision medicine, thanks to the new biological treatment, to date, there is no biological treatment available for COPD. COPD is generally a neutrophils-predominant disease but approximately 40% of patients with COPD had also an eosinophilic airway inflammation. Recent findings: different Phase III trials have been recently performed to evaluate the efficacy and safety of several biological treatments, mostly against eosinophilic inflammation and, to date, some of this trial, still ongoing have promising results. Summary: This review resumes the rationale, the attempts of biological treatment in COPD and latest promising results.

FDA approves first monoclonal antibody for COPD

FDA approves 100th monoclonal antibody product

Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

FDA approves first telomerase inhibitor

FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor

FDA approves ADC Therapeutics’ loncastuximab tesirine, ushering in a new cytotoxic payload

Network Meta-Analysis of the Efficacy and Safety of Monoclonal Antibodies and Traditional Conventional Dichotomous Agents for Chronic Obstructive Pulmonary Disease

FDA approves Merck & Co's pulmonary arterial hypertension drug sotatercept

FDA approves first two drugs for rare Niemann–Pick disease

Turning a Molecule into a Medicine: the Development of Indacaterol as a Novel Once-Daily Bronchodilator Treatment for Patients with COPD

FDA approves l-amino acid decarboxylase deficiency gene therapy

Next generation of anti-inflammatory therapy for COPD?

How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?

Penpulimab: First Approval

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Sixty seconds on . . . asthma injections

Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023

Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma

Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy

Revefenacin: First Global Approval

COPD and biologic treatment: state of the art